Executive Summary

The AI-Powered Medical Devices Market stood at 29 USD Billion in 2025 and is set to reach 109 USD Billion by 2035, a CAGR of 14.2% across the forecast period. Growth builds on a reporting base dating to 2020.

Adoption advances on two fronts: imaging hardware carrying embedded diagnostic algorithms, and software platforms that convert scanner and sensor output into clinician-facing read support, cleared under the EU’s Regulation (EU) 2017/745 conformity-assessment route.

North America held 43.0% of the market in 2025, ahead of Europe at 30.0% and Asia Pacific at 22.0%. Hardware led the component split, and medical imaging and diagnostics led among applications.

The steepest constraint is compliance cost: EU MDR conformity assessment and post-market surveillance add time before a device reaches hospital tender. Vendors compete chiefly on clearance status and clinical evidence.

Key Takeaways

• Valued at USD 29.0 Billion in 2025, reaching USD 108.96 Billion by 2035 at a 14.20% CAGR.
• Hardware led the Component axis, ahead of Software and Services.
• Medical Imaging & Diagnostics led applications, ahead of Patient Monitoring.
• North America held 43.0% share, ahead of Europe’s 30.0%.
• EU Regulation 2017/745 anchors device clearance across Europe.
• MDR conformity assessment and surveillance costs slow market entry.

Market Definition and Scope

The AI-Powered Medical Devices Market covers hardware, software and services that embed machine-learning inference into clinical equipment, spanning imaging scanners, wearable and bedside sensors, surgical robots and embedded processors, alongside diagnostic and monitoring algorithms, platforms and the deployment, integration, support and consulting services hospitals, ambulatory centres and diagnostic labs require to operate them.

Excluded are conventional, non-AI diagnostic hardware and generic hospital IT systems that perform no algorithmic analysis of patient data, and pharmaceutical compounds themselves, as distinct from the AI platforms used to discover them.

Growth Drivers and Restraints

Imaging and Diagnostic Hardware Absorb the Largest Share of Clinical AI Investment

Hospitals route AI budgets first toward imaging scanners, sensors and embedded processors, the equipment layer that must be in place before diagnostic software can run. Medical imaging and diagnostics is the largest application area, with patient monitoring and AI-assisted therapeutics following as secondary demand centers. In the United States, algorithm-driven imaging tools typically clear the FDA’s 510(k) or De Novo pathway; in the European Union, the same devices route through Regulation (EU) 2017/745 conformity assessment and CE marking before a hospital can procure them.

Reimbursement Coding Is Turning Pilot Deployments Into Paid Clinical Workflow

Software adoption follows a second step: once imaging or monitoring hardware is installed, algorithms only scale when a procedure or interpretation carries a reimbursement code. In the United States, CMS coverage decisions and CPT/HCPCS coding determine whether a hospital’s AI-assisted therapeutics or monitoring workflow is paid for on an ongoing basis, converting single-site pilots into standard-of-care tools. Clinical validation supporting those coverage decisions follows ICH Good Clinical Practice standards, which govern the trial evidence behind personalized treatment-planning and chronic-disease-management algorithms.

Surgical Robotics and Drug-Discovery Platforms Are Widening the Addressable Hardware and Software Base

Robotic-assisted surgery spans orthopedic, neurosurgical, cardiovascular and general procedures, each requiring its own navigation hardware and preoperative-planning software, which widens processor, sensor and platform demand beyond diagnostic imaging alone. New robotic surgical systems typically clear the FDA’s De Novo pathway before commercial launch. Separately, drug-discovery platforms that run target identification, compound screening and clinical-trial optimization draw on NIH’s ClinicalTrials.gov registry data to validate trial-design algorithms, pulling computational demand into the market from outside direct patient care.

EU MDR Conformity and Post-Market Surveillance Add Cost Before Launch

Regulation (EU) 2017/745 requires device makers to classify each AI-enabled product, operate a quality- and risk-management system, compile technical documentation and clinical or performance evidence, complete conformity assessment and maintain post-market surveillance before CE marking is granted. That structural cost falls hardest on smaller software developers building diagnostic and monitoring algorithms, which lack the regulatory-affairs staff that larger imaging-hardware manufacturers already run for existing device lines.

Clinician Workflow Integration Lags Device Approval

Approval and reimbursement clearance do not guarantee use: radiologists and surgeons must trust an algorithm’s output before folding it into daily practice, and hospital IT teams must integrate new software with existing picture-archiving and electronic-record systems. Data-handling obligations under HIPAA and GDPR add a further review step for any AI tool that touches patient-level imaging or monitoring data, slowing rollout timelines in ambulatory and homecare settings.

Market Trends

Imaging Read-Support Algorithms Are the Base Layer AI Vendors Build Outward From

Diagnostic imaging remains the largest AI application, with radiology, mammography, ultrasound and MRI systems the first to carry read-support algorithms, while patient monitoring and AI-assisted therapeutics follow as the next-largest demand centers. Most imaging-focused software as a medical device clears the FDA’s 510(k) pathway, which has made radiology the proving ground hospital buyers reference first when weighing reimbursement coding against existing standard of care. Over the forecast period, vendors that built imaging read-support are porting the same architecture into cardiac and glucose monitoring and chronic-disease treatment planning, extending label claims beyond the original indication.

Robotic-Assisted Surgery Is Extending AI From the Reading Room Into the Operating Room

Surgical navigation and robotic-assisted platforms are moving orthopedic, neurosurgical, cardiovascular and general procedures onto AI-guided systems that pair preoperative planning software with intraoperative sensor feedback. New systems in this category typically clear the FDA’s De Novo pathway, reserved for novel-risk device types without an existing predicate; most of this hardware is recent to market and still building the case for consistent reimbursement across payers. As simulation and training modules mature, demand shifts from single flagship robots toward a wider installed base across general-surgery departments, and with it the pull-through consumable volume that follows each placement.

Drug-Discovery Platforms Are Pulling AI Demand Upstream of Patient Care

Target identification, compound screening, biomarker discovery and clinical-trial optimization now draw on the same machine-learning architectures used in diagnostic imaging, pulling computational demand upstream into pharmaceutical research rather than direct patient care. Platforms that optimize trial design increasingly validate their models against NIH’s ClinicalTrials.gov registry data, linking discovery-stage software to the same regulatory evidence base agencies use downstream when reviewing an indication for approval. As biologics and biosimilar pipelines expand, discovery-stage AI spend grows alongside, rather than instead of, the clinical and imaging segments that carry the market’s reimbursement and market-access weight.

Segment Analysis

By Component

• Hardware (largest) – Physical AI-enabled equipment such as imaging scanners, wearable sensors, surgical robots, and embedded processors that capture or act on patient data
• Processors

• CPU
• GPU
• FPGA
• ASIC

• Sensors
• Memory Devices
• Software – Algorithms, machine learning models, and platforms that analyze medical data for diagnosis, monitoring, treatment planning, or workflow automation

• Solutions
• Platforms
• Services – Installation, integration, training, maintenance, and consulting support that help providers deploy and operate AI-enabled medical devices

• Deployment & Integration
• Support & Maintenance
• Consulting

Hardware led the AI-powered medical devices market in 2025. Providers must first own the imaging scanners, wearable sensors, surgical robots and embedded processors that capture patient data before any algorithm has something to analyze, so capital budgets still concentrate on equipment rather than code. Within hardware, processors, sensors and memory devices carry the bulk of that spend, since every bedside or imaging application depends on onboard compute to run inference where care is delivered. Software is expected to grow fastest over the forecast period. Hospitals that have already installed AI-ready scanners and monitors are now layering diagnostic and workflow algorithms onto that base rather than replacing it, and per-study and platform licensing lets vendors monetize the same install base repeatedly.

By Application

• Medical Imaging & Diagnostics (largest) – AI software that analyzes radiology, pathology, or other imaging scans to detect, classify, or quantify abnormalities for clinician review

• X-ray
• MRI
• Ultrasound
• Mammography
• Patient Monitoring – Wearable or bedside devices embedded with AI algorithms that continuously track vital signs and physiological data to flag deterioration or anomalies

• Remote Patient Monitoring
• Vital Signs Monitoring
• Cardiac Monitoring
• Glucose Monitoring
• AI-Assisted Therapeutics – Devices or software that use AI to personalize, guide, or optimize treatment delivery, such as dosing, radiotherapy planning, or rehabilitation protocols

• Radiotherapy Planning
• Robotic Therapy
• Personalized Treatment Planning
• Chronic Disease Management
• Surgery & Robotics – Robotic surgical systems and AI-enabled navigation tools that assist surgeons with precision movement, planning, and intraoperative guidance during procedures
• Robotic-Assisted Surgery

• Orthopedic Surgery
• Neurosurgery
• Cardiovascular Surgery
• General Surgery

• Surgical Navigation
• Preoperative Planning
• Surgical Simulation & Training
• Drug Discovery – AI platforms and computational tools that model molecular interactions, screen compounds, and predict drug candidates to accelerate pharmaceutical research

• Target Identification
• Drug Screening & Design
• Clinical Trial Optimization
• Biomarker Discovery

Medical Imaging & Diagnostics led the application axis in 2025. Imaging produces the largest volume of labeled, standardized data of any clinical workflow, spanning X-ray, MRI, ultrasound and mammography, and radiology carries the deepest bench of cleared algorithms of any AI application, giving hospitals a lower-risk entry point than newer categories. Surgery & Robotics is expected to grow fastest, pulled by the extension of robotic-assisted platforms beyond general surgery into orthopedic, neurosurgical and cardiovascular procedures. Surgical navigation and preoperative planning tools let systems that already own a robotic platform add AI-guided modules procedure by procedure, rather than committing capital to an entirely new device category, which shortens the sales cycle for each incremental application.

Regional Analysis

North America held 43.0% of the AI-powered medical devices market in 2025, the largest share of any region tracked. Demand concentrates around a domestic vendor base, GE HealthCare, Intuitive Surgical and Johnson & Johnson MedTech chief among them, and purchasing runs through integrated delivery networks and group purchasing organizations that negotiate hardware, software and service contracts at system scale rather than hospital by hospital. CMS reimbursement coding for AI-assisted imaging and monitoring gives providers a defined path to bill for algorithm-supported care, and that billing clarity is itself a reason vendors prioritize US launches.

Europe accounted for 30.0% of the market in 2025. Manufacturers must classify each device under Regulation (EU) 2017/745, operate a quality- and risk-management system, compile technical and clinical documentation, complete conformity assessment and affix CE marking before an algorithm reaches a hospital imaging suite. That compliance load rewards incumbents already carrying MDR certification, Siemens Healthineers and Philips among them, and slows the pace at which smaller AI-diagnostics entrants can bring a newly CE-marked product to a national tender in Germany or France.

Asia Pacific held 22.0% of the market in 2025, the smallest of the three regions tracked but the one where approval pathways are moving quickest. Japan’s PMDA and China’s NMPA have each revised device clearance frameworks to accommodate software-driven diagnostics rather than treating every algorithm update as a new hardware submission. Canon Medical Systems’ manufacturing base in Japan anchors regional supply of AI-ready imaging hardware, giving the region a domestic source of the sensors and scanners that AI applications depend on.

Competitive Landscape

The AI-powered medical devices market is led by a group of established, diversified medical technology companies rather than a single dominant vendor, with a smaller set of computing and diagnostics specialists competing alongside them for the software and services layer. Competition centers on regulatory approval status and label breadth, since a cleared indication is what lets a device be sold at all, and on reimbursement coverage and coding, which determines whether a hospital can bill for algorithm-assisted care once it is installed. Installed base matters as much as either: vendors with imaging or robotic platforms already inside a hospital can attach new AI modules to that base, while newer entrants must win a first placement before any software revenue follows. Manufacturing scale and quality record round out the basis of competition for hardware-heavy segments such as sensors and processors.

Named competitors include Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic plc, Johnson & Johnson MedTech, Intuitive Surgical, Inc., Abbott Laboratories, NVIDIA Corporation, Tempus AI, Inc. and Canon Medical Systems Corporation.

Strategic Outlook

The clearest whitespace sits in surgery and robotics, where AI-guided navigation and preoperative planning can be sold into hospitals that already own a robotic platform. That path favors incumbents with an installed base, and it depends on payers extending coding beyond imaging into intraoperative guidance.

Component mix should keep shifting from hardware toward software and services as the installed base of AI-ready scanners and monitors matures, with buyers increasingly evaluating vendors on algorithm performance and reimbursement fit rather than on equipment specifications alone.

AI-Powered Medical Devices Market Report Scope